Innate Pharma (IPHA) — Long-term Investment Intensity
Innate Pharma (IPHA) has a Long-term Investment Intensity of 16.7% as of December 2025. Long-term investments of $10.46 Million represent 16.7% of total assets of $62.69 Million. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. Check IPHA asset resilience ratio to evaluate the company's liquid asset resilience ratio.
LT Investment Intensity
Long-term Investments
Total Assets
Country
Innate Pharma Long-term Investment Intensity (2015–2025)
This chart shows how Innate Pharma's Long-term Investment Intensity has evolved across 11 annual periods from 2015 to 2025. As of December 2025, the intensity stands at 16.7%, reflecting long-term investments of $10.46 Million against total assets of $62.69 Million USD. For the complete balance sheet picture, see IPHA current and non-current assets.
Annual Long-term Investment Intensity for Innate Pharma (2015–2025)
The table below presents the year-by-year Long-term Investment Intensity for Innate Pharma from 2015 to 2025, covering 11 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. Read Innate Pharma total liabilities for a breakdown of total debt and financial obligations.
| Year | LT Investment Intensity | LT Investments (USD) | Total Assets | Change (pp) |
|---|---|---|---|---|
| 2025 | 16.7% | $10.46 Million | $62.69 Million | ▲ +7.4 pp |
| 2024 | 9.3% | $10.28 Million | $111.06 Million | ▲ +3.7 pp |
| 2023 | 5.6% | $9.80 Million | $175.19 Million | ▼ -11.3 pp |
| 2022 | 16.9% | $35.12 Million | $207.86 Million | ▲ +2.0 pp |
| 2021 | 14.9% | $39.88 Million | $267.50 Million | ▲ +2.2 pp |
| 2020 | 12.7% | $38.93 Million | $307.42 Million | ▲ +3.4 pp |
| 2019 | 9.2% | $37.01 Million | $401.36 Million | ▲ +1.4 pp |
| 2018 | 7.8% | $35.18 Million | $451.22 Million | ▼ -15.9 pp |
| 2017 | 23.7% | $60.47 Million | $255.02 Million | ▲ +12.0 pp |
| 2016 | 11.7% | $32.98 Million | $281.58 Million | ▼ -0.1 pp |
| 2015 | 11.8% | $36.10 Million | $305.96 Million | — |